Journal of Clinical Medicine (Sep 2021)

The Two-Step Treatment for Giant Hepatic Hemangiomas

  • Angelo Della Corte,
  • Rebecca Marino,
  • Francesca Ratti,
  • Diego Palumbo,
  • Giorgia Guazzarotti,
  • Simone Gusmini,
  • Luigi Augello,
  • Federica Cipriani,
  • Guido Fiorentini,
  • Massimo Venturini,
  • Luca Aldrighetti,
  • Francesco De Cobelli

DOI
https://doi.org/10.3390/jcm10194381
Journal volume & issue
Vol. 10, no. 19
p. 4381

Abstract

Read online

The aim of the present study is to analyze the feasibility and the impact of a two-step approach in the treatment of giant hemangiomas (GH) i.e., exceeding 10 cm in maximum diameter, consisting of transarterial embolization (TAE) followed by laparoscopic liver resection (LLR). Ten patients with 11 GH were treated with TAE and subsequent LLR between 2017 and 2020 (Group A). A matched cohort of 10 patients with GH treated with upfront LLR between 2014 and 2017 was identified for comparison (Group B). Data were analyzed regarding intraoperative and postoperative outcomes, including successful completion of LLR, morbidity, and mortality. Successful microparticle embolization of the GH-feeding arteries was performed in all patients in group A. In three cases a liquid embolic agent (Squid-18) was also injected to obtain complete embolization. No complications were observed after TAE. Successful surgery was performed after a mean time interval of 2.2 days from TAE without any case of conversion to laparotomy. Statistically significant differences between group A and group B were found in intraoperative blood loss (250 ± 200 vs. 400 ± 300 mL, p = 0.039), operative time (245 ± 60 vs. 420 ± 60 min, p = 0.027), and length of stay (5 ± 1 vs. 8 ± 2 days, p = 0.046). Our data suggest that two-step TAE + LLR might be a safe and effective option for surgical treatment of GH >10 cm.

Keywords